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Background: None of the HIV T-cell vaccine candidates that have reached advanced clinical testing have been
able to induce protective T cell immunity. A major reason for these failures may have been suboptimal T cell
immunogen designs.
Methods: To overcome this problem, we used a novel immunogen design approach that is based on
functional T cell response data from more than 1,000 HIV-1 clade B and C infected individuals and which
aims to direct the T cell response to the most vulnerable sites of HIV-1.
Results: Our approach identified 16 regions in Gag, Pol, Vif and Nef that were relatively conserved and
predominantly targeted by individuals with reduced viral loads. These regions formed the basis of the
HIVACAT T-cell Immunogen (HTI) sequence which is 529 amino acids in length, includes more than 50 optimally
defined CD4+ and CD8+ T-cell epitopes restricted by a wide range of HLA class I and II molecules and covers viral sites
where mutations led to a dramatic reduction in viral replicative fitness. In both, C57BL/6 mice and Indian rhesus
macaques immunized with an HTI-expressing DNA plasmid (DNA.HTI) induced broad and balanced T-cell responses
to several segments within Gag, Pol, and Vif. DNA.HTI induced robust CD4+ and CD8+ T cell responses that were
increased by a booster vaccination using modified virus Ankara (MVA.HTI), expanding the DNA.HTI induced response
to up to 3.2% IFN-γ T-cells in macaques. HTI-specific T cells showed a central and effector memory phenotype with a
significant fraction of the IFN-γ+ CD8+ T cells being Granzyme B+ and able to degranulate (CD107a+).
Conclusions: These data demonstrate the immunogenicity of a novel HIV-1 T cell vaccine concept that induced
broadly balanced responses to vulnerable sites of HIV-1 while avoiding the induction of responses to potential decoy
targets that may divert effective T-cell responses towards variable and less protective viral determinants.
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HIV-1 infection induces strong and broadly directed
HLA class I and class II restricted T-cell responses, for
which some specific epitopes and restricting HLA alleles
have been associated with relative in vivo virus control
or lack thereof [1-3]. Among these, CD8+ cytotoxic T
lymphocytes (CTL) responses to HIV-1 Gag have most
consistently been associated with reduced viral loads in
both HIV-1 clade B- and C-infected cohorts [2,4]. This
is in line with data from post-hoc analyses of the STEP
vaccine trial, where individuals in whom vaccine-induced
responses targeted ≥3 different Gag epitopes achieved a
lower viral load than subjects without Gag responses [5].
CD4+ T-cell responses to Gag have also been associated
with relative HIV-1 control [6,7]. However, it remains un-
clear whether the relative benefit of Gag is due to high
protein expression levels, rapid representation of viral
particle-derived CTL epitopes [8], reduced susceptibility
of Gag-specific CTL to Nef-mediated immune evasion
strategies [9] or particular amino acid composition and in-
herently greater immunogenicity [10]. In addition, the ele-
vated level of conservation of Gag across viral isolates [11]
and the severe fitness reductions caused by CTL escape
variants [12-16] may provide Gag-specific T-cell responses
with a particular advantage. At the same time, it is also
clear that not all Gag-specific responses exert the same
antiviral activity, suggesting that a rational selection of
Gag components could help focus vaccine induced re-
sponses onto the most protective targets. The same likely
applies for all other viral proteins as well, as they may con-
tain some regions that are of particular value for inclusion
in a vaccine while other regions or proteins may induce
less useful T cell responses. As such, effective vaccine de-
sign should probably aim to induce broad and evenly dis-
tributed responses to conserved and vulnerable sites of
the virus while avoiding the induction of responses to re-
gions that can be highly immunogenic but that may act as
potential “decoy” targets and divert responses away from
more relevant targets [17-22].
The failure of various T-cell vaccine candidates ex-
pressing entire HIV-1 proteins in large human clinical
trials and data from post-trial analyses suggesting a sieve
effect on the infecting viral strains, indicate the urgent
need to improve vaccine immunogen design [23-26].
Here, we describe a rational design and pre-clinical test-
ing of a novel approach to HIV-1 T cell immunogen
development and its implication for HIV-1 control.
Starting with a comprehensive screening of large co-
horts of clade B and C HIV-1-infected individuals, we
identified viral targets associated with relative HIV-1
control [27,28]. These earlier analyses in aggregate
identified 26 regions in HIV-1 Gag, Pol, Vif and Nef
proteins that (i) were preferentially targeted by indi-
viduals with low viral loads and largely independenton beneficial HLA class I genotypes, (ii) turned out
to be more conserved than the rest of the proteome,
and (iii) elicited responses of higher functional avidity
and broader variant cross-reactivity than responses to
other regions. These identified regions provided the
basis for a polypeptide sequence that is designed to
a) contain epitope-rich regions in the context of a broad
HLA class I and class II allele coverage, b) induce re-
sponses to subdominant epitopes associated with viral
control and c) focus the vaccine-induced response onto
the most vulnerable targets in the viral proteome. The
conserved elements (CE) immunogen designs, although
modified using immune response and virologic control
data, was driven first by sequence conservation [17-19].
The rational design of this novel HTI sequence also differs
conceptually from other approaches that have either been
based on full protein sequences [23-25], on very short,
conserved segments of the virus [29,30] select conserved
CD8 T cell epitopes [31] or other approaches that attempt
to cover viral diversity [32-35] and which did not in-
corporate human immune reactivity data as the base
of their designs. The immune responses observed in
preclinical testing in C57BL/6 mice and Indian rhesus
macaques show the expected broadly directed re-
sponses and warrant further development in human
clinical trials.
Methods
HIV-1 infected patients and human PBMC samples for
ELISPOT analyses
Chronically HIV-1 infected individuals not receiving
antiretroviral treatment that fulfilled the following criteria
were recruited from the HIV Unit in Hospital Germans
Trias i Pujol, Badalona and Hospital de la Vall d’Hebron,
Barcelona, Spain: chronic HIV-1 infection with (i) persist-
ent undetectable viral loads (Elite controllers, n = 38),
(ii) stable plasma HIV-1 RNA levels <2,000 copies/ml
(Viremic controllers, n = 27), and (iii) non-controlled
viral replication with current plasma HIV-1 RNA
levels >50,000 copies/ml (Non-controllers, n = 30) (Table 1).
The study was approved by the Institutional Review Board
of both participating hospitals, and all individuals pro-
vided written informed consent before entering the
study. HLA genotypes were heterogeneous in all groups
(data not shown). PBMC were processed within 4 h after
venepuncture and cells stored at liquid nitrogen until use.
A set of 410 overlapping-peptides (18-mers OLPs) was
used to screen for HIV-specific T-cell responses to the full
HIV-1 proteome. The peptides spanned all HIV-1 proteins
and were used in a matrix layout of 6–12 peptides per
pool for comprehensive screening as previously described
[36]. All positive wells in the matrix screen were con-
firmed the following day on a single-peptide level. Results
are presented as the contribution of responses targeting
Table 1 Clinical data of cohort for human PBMC samplesa and HLA class I allele distribution
Group (N) HIV-1 RNA levels (copies/ml) CD4+ T cells (cells/mm3) Protective HLA alleles
EC (38) UDb 826 (606; 946) B*27 (8%) B*57 (26%) B*58 (3%)
VC (27) 540 (265; 1,182) 642 (498; 1,014) B*27 (4%) B*57 (18%) B*58 (7%)
NC (30) 140,00 (58,000; 415,000) 128 (59; 211) B*27 (7%) B*57 (7%) B*58 (7%)
aValues expressed as median (IQR).
bUD, undetectable viremia (<49 copies/ml).
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response to the full HIV-1 proteome.
DNA.HTI and MVA.HTI vaccines
The HTI plasmid DNA (plasmid 298H) contains the
expression-optimized [37-39] HTI open reading frame
inserted into a pCMVkan vector comprising a plasmid
backbone optimized for growth in bacteria, the human
cytomegalovirus (CMV) promoter without any introns, the
optimized HTI gene, the bovine growth hormone (BGH)
polyadenylation site, and the kanamycin resistance gene.
The HTI gene contains the human GM-CSF signal peptide
(AA 1–17; Genbank accession Nr. NP_000749) at the N
terminus as a means to enhance translocation into the
Endoplasmatic Reticulum [40]. A FLAG-tag was added at
the C–terminus (HTI-FLAG) for expression analysis in
transfected HEK293 cells. RNA/codon optimized clade B
(strain HXB2) genes for full-length p55gag (plasmid 114H),
Pol (plasmid 133H), NefTatVif fusion (NTV, plasmid
132H), and LAMP-Pol (plasmids 128H) and LAMP-NTV
(plasmids 129H), fusion proteins with the lysosomal asso-
ciated membrane protein 1 (LAMP-1) [40] were used. The
IL-12 DNA (plasmid AG157) produces the expression-
optimized rhesus macaque IL-12 cytokine [41]. Plasmid
DNAs were produced in E.coli DH10B (Invitrogen), and
the purified endotoxin-free DNAs (Qiagen) were resus-
pended in sterile water (Gibco).
A recombinant MVA expressing the HTI gene was gen-
erated as described previously [42,43]. Briefly, chicken em-
bryo fibroblast (CEF) cells grown in Dulbeco’s Modified
Eagle’s Medium supplemented with 10% FBS, penicillin/
streptomycin and glutamine (DMEM 10) were infected
with parental MVA and transfected using Superfectin
(Qiagen) with DNA.HTI. These cells were MoFlo single-
cell sorted into 96-well plates and these were used to cul-
ture recombinant virus upon addition of fresh CEF. Those
wells containing suitably infected cells were harvested and
screened by PCR to confirm identity and test purity.
Plaque picking was performed using CEF until the culture
was free of parental virus, as determined by PCR, after
which a master virus stock was grown, purified on a 36%
sucrose cushion, titered and stored at −80°C until use.
HTI DNA expression upon transient transfection
Briefly, 1 × 106 human HEK 293 cells grown in complete
DMEM plus 10% fetal bovine serum (FBS) were platedon to 60-mm tissue culture dishes and allowed to adhere
overnight. Cells were transfected by CaPhosphate DNA
co-precipitation with a total of 7 μg of DNA (100 ng or
250 ng of the plasmid DNA adjusted to 7 μg with Bluescript
DNA). Six hours after transfection the medium was re-
placed with 3 ml of DMEM supplemented with 2% of
FBS. After 24 and 48 hrs the cells and the superna-
tants were collected in 0.5X RIPA (Boston BioProducts,
Ashland, MA). Protein expression was analyzed by
Western immunoblots using 10% or 12% sodium do-
decyl sulfate polyacrylamide gels (Nu-Page Bis-Tris,
NuPAGE, Invitrogen, Life Technologies Corp., Carlsbad,
CA) and blotted onto nitrocellulose membranes which
were probed with a anti-FLAG-HRP antibody (dilution
1:4000, Sigma) or a goat anti-p24gag antibody (dilution
1:3000, provided by L. Arthur, SAIC, NCI, Frederick)
followed by anti-goat IgG-HRP labeled antibody (dilution
1:10,000; Calbiochem, EMD chemicals, Gibbstown, NJ).
As control, the membranes were probed with anti-human
pan-actin antibody (clone C4, EMD Millipore, Billerica,
MA) at a dilution of 1:10,000. The bands were visualized
using the enhanced chemiluminescence (ECL) plus West-
ern blotting detection system (GE HealthCare, Piscataway,
NJ). HeLa-derived HLtat cells were plated with 2 × 105
cells/35-mm glass-bottomed plate and 24 hrs later were
transfected with 500 ng of the DNA.HTI-FLAG plasmid.
The next day, the cells were fixed with 4% paraformalde-
hyde in PBS, permeabilized with 0.5% Triton X-100 in
PBS and incubated with mouse anti-FLAG antibody
(Sigma) at 1:1,000 dilution, followed by incubation with
anti-mouse Alexa-fluor 488 and DAPI at 1:1000 dilution.
The cells were visualized on a Zeiss Observer Z1 fluores-
cent microscope using Zeiss Axiovision software (Carl
Zeiss Microimaging, GmbH, Göttingen, Germany).
Vaccination of C57BL/6 mice
Groups of five female C57BL/6 (6 to 8 weeks old) were
obtained from Charles River Laboratories, Inc. (Frederick,
MD) and were housed at the National Cancer Institute,
Frederick, MD, in a temperature-controlled, light-cycled
facility. The mice were immunized with DNA.HTI or
DNA.COMB consisting of gag, pol and NTV (nef, tat, vif)
expression plasmids using doses of 20 μg DNA per
mouse. The DNA was delivered by intramuscular injection
followed by in vivo electroporation by ELGEN® constant
current electroporation device (Inovio Pharmaceuticals,
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clade B (expressing complete clade B p55 Gag protein) in
combination with DNA.Pol (expresses full-length Pol
protein) and DNA.NTV (expressing a chimeric protein
of Nef, Tat and Vif) plasmids. The animals were vacci-
nated twice (0 and 3 weeks or 0 and 4 weeks), and were
sacrificed 2 weeks after the last vaccination when spleens
and blood were collected for the analysis of cellular and
humoral responses.
For heterologous prime/boost experiments, groups of
6 C57BL/6 mice (Harlan Laboratories Ltd., Barcelona,
Spain) were used in the Hospital Germans Trias i Pujol
Animal facility. Mice were primed intramuscularly with
100 μg of DNA.HTI (2, 3 or 4 vaccinations) followed by
a 106 pfu of MVA.HTI boost, as indicated. All vaccina-
tions were separated by three weeks. All mice were
sacrificed two weeks after the last vaccination when sple-
nocytes and serum were harvested for immunogenicity
studies. Spleens were removed and pressed individually
through a cell strainer (Falcon) using a 5-ml syringe rub-
ber plunger. Following red blood cell lysis, splenocytes
were washed and resuspended in RPMI 1640 supple-
mented with 10% FCS, penicillin/streptomycin (R10) and
frozen until use.
Overlapping peptides and distribution of peptide pools
To allow for comparisons in immunogenicity among
groups of animals, sequences of the immunogenic seg-
ments contained in HTI were confirmed to be >95%
matched with the sequences from the full-length pro-
teins expressed by control DNAs. Ex vivo immune ana-
lyses of murine experiments in which DNA expressing
full proteins were used, employed a previously described
overlapping peptide set (410 18-mers OLP) spanning the
entire viral proteome [36]. Peptides were 18-mers varying
from 15–20 amino acids in length and overlapping by
10 amino acids, designed using the PeptGen algorithm
at the Los Alamos HIV database [44] and based on the
2001 consensus-B sequence [2,36]. To assess responses
to entire Gag, Pol, Nef, Tat and Vif and the relative
distribution of responses to regions covered by HTI
T-cell immunogen, a set of peptide pools was de-
signed that consisted of 6 pools for Gag (11 peptides/
each), 8 for Pol (16 or 17 peptides/each), 2 for Nef
(13 and 14 peptides/each), 1 for Tat (12 peptides) and
2 for Vif (12 peptides/each) proteins. A second pep-
tide set consisting of 8 peptide pools covered the pro-
tein subunits spanning the 16 segments included in
the HTI and was used in the experiments where electro-
poration was performed. For experiments that assessed
the immune responses after heterologous prime/boost
vaccinations and for analyses that measured the potential
immunogenicity of junctional epitopes an overlapping
peptide set of 147 peptides of 15 amino acids in length(overlapping by 11 residues) spanning the entire HTI (in-
cluding the leader sequence and linkers regions) was syn-
thesized. For mice experiments, HTI peptides were
pooled into 18 different pools, according to protein sub-
units and considering a similar number of peptides per
pool (1 pool for the signal peptide sequence, n = 4 pep-
tides; 7 pools for Gag, n = 8-11 peptides/each; 7 pools
for Pol, n = 5-11 peptides/each; 2 pools for Vif, n = 6-8
peptides/each and 1 pool for Nef, n = 2 peptides). In
macaque experiments and to assess breadth of vaccine in-
duced responses, peptides were pooled and distributed
covering each HTI segment individually (S1-S16).Murine IFN-γ ELISPOT assay
ELISPOT assay was performed by using a mouse IFN-γ
ELISPOT kit (ALP) (Mabtech AB, Stockholm, SE) fol-
lowing the manufacturer’s instructions with minor modi-
fications. For all assays, frozen splenocytes were thawed
and rested for 5 hrs at 37°C in R10 medium before use.
Cells were added at an input cell number of 4 × 105
cells/well in 140 μl of R10 in 96-well polyvinylidene
plates (Millipore Corp., Bedford, MA) alone or with
HIV-1- specific peptide pools (14 μg/ml final concentra-
tion for each peptide) for 16 hrs at 37°C in 5% CO2.
Concanavalin A (Sigma-Aldrich Corp., Saint Louis,
MO), at 5 mg/ml, was used as a positive control. The
plates were developed with one-step 5-bromo-4-chloro-
3-indolyl phosphate/Nitroblue Tetrazolium (BCIP/NBT,
Bio-Rad Laboratories, Inc., Irvine, CA). The spots on the
plates were counted using an automated ELISPOT
reader system (CTL Analyzers LLC, Cleveland, OH)
using ImmunoSpot software and the magnitude of re-
sponses was expressed as spot forming cells (SFC) per
million splenocytes. The threshold for positive responses
was defined as at least 5 spots per well and responses ex-
ceeding the mean number of spots in negative control
wells plus 3 standard deviations of the negative control
wells and three times the mean of negative control wells,
whichever was higher.Humoral immune response analysis
Humoral responses were analyzed in pooled mice plasma.
Binding antibodies to HIV-1 Gag were detected by
Western immunoblot using cell extracts from HEK293
cells transfected with 1 μg of Gag and Gag-Pol expression
vectors, separated on 12% SDS-PAGE, and the membranes
were probed with pooled plasma (at a 1:100 dilution) and
the bands were visualized by anti-mouse IgG-HRP anti-
body (1:10,000 dilution, GE Healthcare, Piscataway, NJ).
Serial dilutions of plasma samples were analyzed by stand-
ard HIV-1 clade B p24gag ELISA (Advanced Bioscience
Lab, Rockville, MD), measuring optical absorbance at
450 nm.
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Indian rhesus macaques (R678, R679, R680, R681) were
vaccinated with 2 mg of DNA.HTI together with 0.2 μg
of macaque IL-12 DNA formulated in 0.6 ml of sterile
water (Hospira, Inc., Lake Forest, IL). DNAs were deliv-
ered via intramuscular (IM) injection at two different
sites (0.3 ml each site) followed by in vivo electropor-
ation using the Elgen 1000 device (Inovio, Pharmaceuti-
cals, Inc, Blue Bell, PA). The animals received three
vaccinations with DNA.HTI at 0, 1 and 3 month. After a
rest period of 4.5 months, the animals received a boost
with recombinant MVA.HTI (108 pfu/dose) delivered via
the IM route as a single inoculation. A 2nd MVA.HTI
boost was administered 3 months later. All macaques used
in this study were males and were 3 years of age at the on-
set of the study. Vaccinations were performed under
anesthesia (Ketamine administered at 10 mg/kg) and all
efforts were made to minimize suffering. No adverse ef-
fects were found. None of the animals were euthanized as
part of this study.
Intracellular cytokine staining of macaque PBMC
Macaque PBMC were isolated by Ficoll-hypaque (Histopaque,
Sigma, St. Louis, MO) centrifugation, and cultured in 96-
well plates as described previously [45]. PBMC were stim-
ulated overnight with peptide pools (final concentration of
1 μg/ml for each peptide) in the presence of monensin
(BD Pharmingen, San Diego, CA), Antigen-specific T cells
were monitored by intracellular cytokine staining followed
by polychromatic flow cytometry. The cells were stained
with the following cocktail of cell surface antibodies:
CD3-APCCy7 (clone SP34-2), CD4-V500 (clone L200),
CD95-FITC (clone DX2) (BD Pharmingen), CD8-Alexa
Fluor-405 (clone 3B5, Invitrogen, Carlsbad, CA), CD28-
PerCP Cy5.5 (clone CD28.2, BioLegend, San Diego, CA).
CD107a-eFluor 660 (clone eBioH4A3, eBioscience San
Diego, CA) antibody was added to the cells 10 min
after addition of the peptides. After cell permeabilization
with Cytofix/Cytoperm (BD Biosciences), intracellular
staining was performed using IFN-γ-PE Cy7 (clone B27,
BD Pharmingen) and Granzyme B-PE antibodies (clone
GB12, Invitrogen). In all experiments, PBMC cultured in
medium without peptide pools or stimulated with phorbol
myristate acetate (PMA) and calcium ionophore (Sigma,
St. Louis, MO) were used as negative and positive control,
respectively. Samples were considered positive, if the fre-
quency of the IFN-γ+ T cells of the peptide stimulated
sample was more than 2 fold higher than the frequency
obtained in unstimulated (without peptide) medium only
control sample. At least 105 T cells from each sample were
acquired on an LSR II flow cytometer (BD Biosciences,
San Jose, CA) and the data were analyzed using FlowJo
software (Tree Star, Inc., Ashland, OR). Subsets of antigen-
specific T cells were defined by Boolean gating, includingcentral memory (CD95+ CD28+), effector memory (CD95+
CD28−) and cytotoxic potential (granzyme B and CD107a
expression).
Humoral immune responses of vaccinated macaques
HEK293 cells were transfected with 0.5 μg of HTI-
FLAG expression vector and immunoprecipitated using
anti-Flag M2 affinity gel (Sigma, Catalog Number A2220)
to concentrate the protein 20-fold. The proteins were
separated on 12% SDS-PAGE and transferred to mem-
brane as described above. The membranes were probed
with plasma from the vaccinated macaques at a 1:100 di-
lution, and the bands were visualized using a 1:10,000
dilution of an anti-monkey IgG+, IgA+, IgM + −HRP-
conjugated antibody (cat# 43R-IG050hrp; Fitzgerald
Industries International Inc., MA). The bands were visual-
ized using the enhanced chemiluminescence (ECL) plus
Western blotting detection system (GE HealthCare,
Piscataway, NJ). ELISA was performed using serial 4-
fold dilutions of plasma samples analyzed by standard
HIV-1 clade B p24gag ELISA (Advanced Bioscience
Laboratory, Rockville, MD), measuring optical absorb-
ance at 450 nm.
Statistical analyses
The results are given as medians and interquartile range
as indicated unless otherwise stated. GraphPad Prism
version 4.0 for Windows (San Diego, CA) was used to
compare response rates in both groups and subgroup
analyses. Mann–Whitney test and Wilcoxon matched
paired test were used for unpaired and paired compari-
sons, respectively.
Ethics statement
Chronically HIV-1 infected adult individuals were re-
cruited from the HIV Unit in Hospital Germans Trias i
Pujol, Badalona and Hospital de la Vall d’Hebron, Barce-
lona, Spain through the prospective observational cohort
study named ‘Controllers’. The study was approved by
the Institutional Review Board of Hospital Germans
Trias i Pujol, Badalona and Hospital de la Vall d’Hebron,
Barcelona. All adult subjects provided written informed
consent before entering the study.
C57BL/6 mice used for this study were cared at the
temperature-controlled, light-cycled animal facilities of
National Cancer Institute, Frederick, US and Hospital
Germans Trias i Pujol, Badalona, Spain. The animal user
protocol was approved by the NCI-Frederick Animal
Care and Use Committee (AWA#:A4159-01). Frederick
National Laboratory for Cancer Research is accredited
by AAALAC International and follows the Public Health
Service Policy for the Care and Use of Laboratory Animals.
Procedures involving mice performed at the animal facility
of Hospital Germans Trias i Pujol followed EU normative
Table 2 List of identified beneficial overlapping peptides
(OLP, PR > 1) incorporated in the final T-cell immunogen
design, based on previous analysis [28]
OLP no. Protein Subunit OLP clade B cons sequence
3 Gag p17 EKIRLRPGGKKKYKLKHI
6 Gag p17 ASRELERFAVNPGLL
7 Gag p17 ERFAVNPGLLETSEGCR
10 Gag p17 QLQPSLQTGSEELRSLY
12 Gag p17 SLYNTVATLYCVHQRIEV
23 Gag p24 AFSPEVIPMFSALSEGA
31 Gag p24 IAPGQMREPRGSDIA
34 Gag p24 STLQEQIGWMTNNPPIPV
48 Gag p24 ACQGVGGPGHKARVLAEA
60 Gag p15 GKIWPSHKGRPGNFLQSR
75 Nef - WLEAQEEEEVGFPVRPQV
159 Pol Prt KMIGGIGGFIKVRQYDQI
160 Pol Prt FIKVRQYDQILIEICGHK
161 Pol Prt QILIEICGHKAIGTVLV
163 Pol Prt LVGPTPVNIIGRNLLTQI
171 Pol RT LVEICTEMEKEGKISKI
195 Pol RT LRWGFTTPDKKHQKEPPF
196 Pol RT DKKHQKEPPFLWMGYELH
210 Pol RT EIQKQGQGQWTYQIY
269 Pol Int TKELQKQITKIQNFRVYY
270 Pol Int TKIQNFRVYYRDSRDPLW
271 Pol Int YYRDSRDPLWKGPAKLLW
276 Pol Int KIIRDYGKQMAGDDCVA
405 Vif - VKHHMYISGKAKGWFYRH
406 Vif - GKAKGWFYRHHYESTHPR
424 Vif - TKLTEDRWNKPQKTKGHR
Mothe et al. Journal of Translational Medicine  (2015) 13:60 Page 6 of 23on animal experimentation and were approved by the
Animal Experimentation Ethical Committee from the
Institut d’Investigació Sanitària Germans Trias i Pujol
and the Department d’Agricultura, Ramaderia, Alimentació
i Medi Natural of the Generalitat de Catalunya (DAAM
order number 6390).
Indian rhesus macaques (Macaca mulatta) used in this
study were housed at the Bioqual (formerly Advanced
BioScience Laboratories, Inc.) animal facility. All animals
were cared for and procedures performed under a protocol
approved by the ABL Animal Care and Use Committee
(animal welfare assurance no. A3467-01; protocol no.
AUP572) and USDA Certificate number 51-R-0059. The
macaques were managed according to the animal hus-
bandry program, which aims at providing consistent and
excellent care to nonhuman primates at the vivarium. This
program operates based on the laws, regulations, and
guidelines promulgated by the United States Department
of Agriculture (e.g., the Animal Welfare Act and its regu-
lations, and the Animal Care Policy Manual), Institute for
Laboratory Animal Research (e.g., Guide for the Care
and Use of Laboratory Animals, 8th edition), Public
Health Service, National Research Council, Centers for
Disease Control, and the Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC)
International. The nutritional plan utilized by the Animal
Facility consisted of twice daily feeding of Labdiet 5045
High Protein Primate Diet and food intake was closely
monitored by animal research technicians. This diet was
also supplemented with a variety of fruits, vegetables, and
other edible objects as part of the environmental enrich-
ment program established by the Veterinary staff and en-
richment Technician. Pairing of animals as part of the
environmental enrichment program was managed by the
enrichment technician. All primary enclosures and animal
rooms were cleaned daily with water and sanitized at least
once every two weeks. All macaques (N = 4) used in this
study were males and were 3 years of age at the onset of
the study. Vaccinations were performed under anesthesia
(Ketamine administered at 10 mg/kg) and all efforts were
made to minimize suffering. No adverse effects were
found. None of the animals were euthanized as part of this
study.
Results and discussion
Design of the HIVACAT T-cell immunogen (HTI) covering
targets of effective antiviral T cell responses
We recently reported a systematic analysis of a large set
of human immune data from cohorts of HIV-1 infected
individuals [27,28,36]. In these analyses, more than 1,000
untreated HIV-1 clade B and clade C infected individuals
were screened for anti-HIV T cell responses and regions
of the viral proteome predominantly targeted by subjects
with superior HIV-1 control were revealed. Of the 41018-mer overlapping peptides (OLP) spanning the entire
viral proteome, 26 consensus clade B derived OLP were
identified for which the median viral load in the OLP re-
sponder group was significantly lower than the viral load
in subjects who did not target these OLP (i.e., OLP non-
responders). These beneficial OLP were located in the
HIV-1 Gag (n = 10), Pol (n = 12), Vif (n = 3) and Nef (n = 1)
proteins (Table 2) and overlapped or closely matched the
beneficial regions identified by analogous screening in
HIV-1 clade C-infected subjects [28].
The 26 beneficial OLP were aligned and if located in
close proximity (<4 amino acid residues between one end
and the start of an adjacent beneficial OLP) fused using
the naturally occurring clade B consensus sequence resi-
dues. This resulted in 16 continuous segments with the
precise start and end positions defined after considering
additional residues up- and down-stream of the identified
26 OLP for inclusion. These extensions and truncations
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border so that additional specific epitopes that were con-
sidered important or can be presented as extended length
variants were fully covered [2,3,27,46] (ii) shortening of
segments to exclude immunodominant epitopes for which
no published evidence supports their beneficial effects on
viral control, (iii) extensions to cover flanking regions
known to affect epitope processing [47,48] and (iv) intro-
duction of single amino acid changes to cover common
drug-resistance mutations for which maintained immuno-
genicity of the resistance variants had been reported
[48-50]. Further refinement also included cases where the
reported epitopes were originally not identified in the con-
text of consensus clade B sequence [51] and sequence
truncations to avoid the presence of “forbidden” residues
that are essentially never found on C-terminal ends of
HLA class I restricted T-cell epitopes [44,52]. Finally, two
additional regions in Gag were incorporated to complete
the coverage of previously described hot-spots of CD4+ T-
helper cell activity [53]. These two segments partially
overlapped with two of the most conserved regions of Gag
p24 [19] that had been shown to be preferentially targeted
by HIV-1 controllers and also include the protective B27
KK10 and B14 DA9 CTL epitopes [27]. The final sequence
comprised 16 segments ranging from 11–78 amino acids
in length representing Gag (45%), Pol (44%), Vif (8%) and
Nef (3%) sequences (Table 3). Linkers between segments
consisted of either single, dual or triple alanine residues,
and were included with the aim of inducing preferentialTable 3 Distribution and length of the 16 final HIV-1
segments included in the HTI sequence
HTI segments Length (AA) HIV-1 protein
S1 78 Gag-p17
S2 14 Gag-p24
S3 11 Gag-p24
S4 60 Gag-p24
S5 14 Gag-p24
S6 15 Gag-p24
S7 27 Gag-p15
S8 55 Prt
S9 17 RT
S10 55 RT
S11 34 RT
S12 34 Int
S13 17 Int
S14 26 Vif
S15 19 Vif
S16 13 Nef
Total (incl. linker) 529proteolytic cleavage between segments and to avoid pre-
mature epitope digestion [47,54].
The final linear HTI sequence had a total length of
529 amino acids and included a high density of both
CD8+ and CD4+ T-cell epitopes across all protein sub-
units restricted by at least 42 different HLA alleles (n =
55 well-characterized optimal defined CTL epitopes [55]
and 6 most frequently targeted CD4+ T helper epitopes
in Gag [53], Table 4). Of note, 14 Gag CD4+ T cell ‘pro-
miscuous’ epitopes (recognized in the context of two or
more DRB alleles) [7] were covered by the final HTI se-
quence as well. Importantly, no overrepresentation of
HLA-B27 or HLA-B57 supertype-restricted epitopes was
observed, which is in line with the unbiased general
population screening that provided the data for the iden-
tification of beneficial OLP signal (Figure 1A). The se-
quence was also analyzed for its coverage of particularly
vulnerable immune targets based on recently published
viral fitness data for Gag p24 sequence mutations [56]. Of
the 135 Gag p24 sites analyzed by Rihn and colleagues
[56], 72 were covered by HTI. Of these, 58 (80%) showed
high vulnerability for mutations and caused massive (>50
fold) reductions in viral replicative fitness. This was a sig-
nificantly higher proportion of vulnerable sites than what
was observed for the Gag p24 region that was not covered
by HTI (a total of 37 deleterious mutants among 63 tested
variants, p = 0.005), demonstrating further the preferential
coverage of vulnerable sites by HTI.
To confirm that the final HTI sequence design (i.e., in-
cluding extensions, truncations and substitutions) con-
tained T cell targets preferentially recognized by individuals
with reduced viral loads, an independent cohort of HIV-1
clade B infected individuals was tested for responses to
the HTI sequence and compared to responses to the full
HIV-1 proteome. Data from 38 elite HIV controllers (EC),Table 4 CTL optimal epitopes and CD4+ T-helper epitope
coverage of HTI
Protein
location
# of CTL
epitopesa
# of CD4+ T Helper
Gag epitopes
(>25% targeted)b
# of ‘promiscuous’
CD4+ T cell Gag
peptidesc
Gag-p17 17 3 6
Gag-p24 21 2 6
Gag-p15 3 1 2
Pol-Prt 5
Pol-RT 6
Pol-Int 1
Vif 2
Nef 0
Total 55 6 14
abased on the ‘A’ list of optimal defined HIV-1 CTL epitopes described in
the Los Alamos HIV Immunology Database [55].
b,cdescribed CD4 T-helper epitopes [7,53].
Figure 1 Design of HTI, HLA coverage and translation into HIV-1
control. (A) HLA supertype coverage of all the optimal defined
epitopes included in HTI immunogen [52]. Colors are based on
the allele’s reported relative hazard to develop AIDS (grey, neutral;
black, neutral/rapid progression; white, beneficial) [57,58]. (B) The
relative dominance of the responses induced by OLP covering the HTI
sequence (n = 52) to the complete HIV-1 proteome (n = 410) is shown
in elite controllers (EC, n = 38), viremic controllers (VC, n = 27)
and non-controllers (NC, n = 30). (C) Total IFN-γ ELISPOT responses
(magnitude) against the complete HIV-1 proteome elicited by
consensus B overlapping 18-mer peptide sets (n = 410).
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was collected (Table 1). A significantly stronger focus of
the total virus-specific response on targets covered by the
HTI was observed in both elite controllers (26.5% of total
HIV-1 T-cell reactivity targeting HTI) and viremic con-
trollers (25%) compared to individuals with uncontrolled
HIV-1 infection (14%, p = 0.0066 and p = 0.0263, respect-
ively) (Figure 1B). These differences were not due to the
presence of stronger responses in HIV controllers, as the
total magnitude of responses did not differ between
groups (Figure 1C). Together, these data indicate that the
rational design of HTI resulted in a relatively short, yet
highly immunogenic subunit sequence that was especially
reactive in HIV controllers and covered a particularly high
proportion of vulnerable viral sites.
Expression of HTI plasmid DNA from HEK293 cells
The HTI sequence was RNA-codon optimized to maximize
mRNA processing, transport, stability and translation andwas cloned into the pCMVkan expression vector [59]
(DNA.HTI). To promote production and secretion of the
immunogen, the signal peptide from the human gran-
ulocyte macrophage colony-stimulating factor (GM-CSF)
was added at the amino-terminus of HTI (Figure 2A)
[17,18,40]. Upon transient transfection, we analyzed ex-
pression of the FLAG-tagged HTI by fluorescent mi-
croscopy and found that the protein localized to punctate
foci in the cytoplasm of HeLa cells (Figure 2B). The
localization of HTI protein was also evaluated from cell
extracts and supernatants of transiently transfected
HEK293 cells by Western immunoblots (Figure 2C)
probed with an anti-FLAG (lanes 1–4) or an anti-p24gag
antibody (lanes 5–8). The HTI protein migrated at ~50 kDa
and was only found in the cell-associated fraction
(Figure 2C). We noted lower levels of HTI protein at
48 hrs compared to 24 hrs post transfection (lanes 2
and 4; lanes 6 and 8). To quantitate production from
transfected cells, serial dilutions of the p55gag-FLAG and
HTI-FLAG proteins were analyzed by Western blots using
the common FLAG epitope and a standard FLAG-tagged
p55gag protein. A side-by-side comparison in trans-
fected HEK293 cells showed that expression of p55gag
increased ~2x over time (~280 ng at 24 hrs; ~600 ng
at 48 hrs), while HTI levels were ~2x decreased (~22 ng
at 24 hrs; ~9.5 ng at 48 hrs) (Figure 2D). Thus, these data
indicate that HTI protein accumulates intracellularly
and is significantly less stable than p55gag. This was
further confirmed by the analysis of HTI-FLAG protein
pulled down with anti-FLAG antibody, which allowed the
amount of protein loaded per lane to be increased. The
Western immunoblot analysis revealed several shorter
bands in addition to the full-length HTI protein, possibly
reflecting processed products (Figure 2E).
DNA plasmid vaccination in C57BL/6 mice elicits broad and
balanced T-cell responses to all protein components of HTI
To examine the immunogenicity of HTI, groups of five
C57BL/6 mice were vaccinated twice (0 and 4 weeks) by
intramuscular (IM) injection combined with in vivo elec-
troporation (EP) (Figure 3A). DNA.HTI vaccination was
compared to a control group that received a mixture of 3
plasmids encoding full-length p55gag, Pol and a Nef-
Tat-Vif fusion protein (DNA.COMB). The magnitude
and breadth of the vaccine-induced T-cell response were
assessed in splenocytes collected 2 weeks after the 2nd vac-
cination (week 6) by an IFN-γ ELISPOT assay using two
sets of peptide pools: (i) 8 overlapping peptide pools cov-
ering the HTI sequence and assembled in separate pools
for each protein subunit included in HTI (HTI pool-1 to
pool-8) and (ii) 19 additional peptide pools spanning the
full-length sequences of Gag (n = 6 pools), Pol (n = 8), Nef
(n = 2), Tat (n = 1), and Vif (n = 2). These pools were used
to assess responses to HTI itself and to define the
Figure 2 (See legend on next page.)
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Figure 2 Expression of DNA.HTI. (A) The HTI protein is composed of 16 individual segments arranged linearly and linked via 1–3 alanine amino
acid linkers and contains the GM-CSF signal peptide for better secretion. Total length of HTI protein is 529 aa, including alanine linkers.
(B) Subcellular localization of HTI protein is shown in HeLa-derived HLtat cells transfected with DNA.HTI-FLAG and fixed. The HTI-FLAG
protein was visualized with anti-FLAG primary antibody followed by Alexa-Fluor 488 conjugated secondary antibody and the nuclei were
visualized with DAPI and a merged image is shown. (C) Plasmid DNA (250 ng) expressing HTI or p55gag with or without FLAG were transfected in
HEK293 cells. The cultures were harvested after 24 hrs and 48 hrs and proteins in cell-associated (top panel: 1/100) and extra-cellular (bottom panel:
1/150) fractions were resolved on a 12% NuPAGE Bis-Tris gel. Western immunoblots were analyzed using an anti-FLAG-HRP antibody (lanes 1–4) or a
goat anti-p24gag antiserum followed by anti-goat IgG-HRP labeled antibody (lanes 5–8) and were visualized using enhanced ECL. The membranes
were probed with an anti-beta actin antibody to control for equal loading of the cell-associated fractions. (D) The serially diluted extracts
with cell-associated and extra-cellular fractions for p55gag-FLAG and cell-associated fraction of HTI-FLAG proteins were analyzed together
with FLAG-tagged p55gag protein standard. The HTI-FLAG and p55gag proteins were quantified by fitting standard curve using standard p55gag-FLAG
protein. (E) Analysis of a 20-fold concentrated sample (compared to panel C) containing HTI-FLAG by Western immunoblot using anti-FLAG antibody.
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nated with the full-length protein sequences.
Although the HTI sequence was only a fraction of
the combined length of the full-protein sequence in
the DNA.COMB (529 amino acids vs 2,000 residues),
equally broad responses to the 8 peptide pools covering
the HTI sequence were detected after vaccination with
the DNA.HTI vaccine [median of 4 reactive pools (range
2–5)] or DNA.COMB [median 2 reactive pools (range 1–3),
p > 0.05] (Figure 3B). Similarly, the magnitudes of the HTI-
specific responses were comparable in the two groups
(Figure 3C). Importantly, six of the eight protein subunits
in the HTI immunogen sequence were targeted at least
once in the mice immunized with DNA.HTI, while only 4
peptide pools were reactive in animals vaccinated with
DNA.COMB (p > 0.05, Table 5). In line with this data and
as hypothesized, mice immunized with plasmids encoding
the full-length protein sequences mounted responses
largely (74%) towards regions not covered by the HTI and
showed a strong dominance of Gag-specific T-cell activity
(Figure 3D). Polychromatic flow cytometry analysis further
revealed that the HTI-specific responses in the DNA.HTI
were mediated primarily by CD8+ T cell (not shown). Al-
though Gag was the most potent target in the DNA.HTI
vaccinated animals as well (median of 55% of the total
magnitude), the pattern of responses was shifted to a more
balanced hierarchy (Gag > Pol > Vif > Nef) (Figure 3E),
which was representative of the relative length of the dif-
ferent protein subunits in the HTI immunogen.
To determine the immunogenicity of potential junc-
tional neo-epitopes located between the 16 segments of
the HTI sequence, all individual overlapping peptides
that contained at least one of the three alanine linker
residues were tested. Positive responses were only de-
tectable for the linkers joining segments 4–5, 5–6, 8–9
and 12–13 (Additional file 1: Table S1). Importantly,
flanking OLP harboring at least 8 residues before or
after the AAA sequence also elicited a response in all
but one of these cases, indicating that minor T cell re-
activity to epitopes consisting of the full linker sequence
was induced.Finally, mice were assessed for the induction of
humoral immune responses upon DNA.HTI vaccination
and compared to animals vaccinated with full-length
protein sequences. The ability to recognize full-length
p55gag and its processing products, the p37gag intermediate
(p17gag plus p24gag) and p24gag, was assessed by Western
blot assay using pooled plasma from immunized mice. In-
deed, plasma from DNA.HTI vaccinated mice recognized
the full-length and the processed Gag proteins (Figure 3F).
Similar data were obtained with DNA.COMB vaccinated
mice, although with a stronger signal indicating a higher
antibody titer. Plasma samples were also analyzed by
HIV-1 p24gag ELISA and showed ~2 log lower antibody
titers in HTI-immunized mice compared to mice vacci-
nated with DNA.COMB (Figure 3G). Thus, these two as-
says show that humoral responses induced by pDNA.HTI
vaccination are able to recognize the mature proteins
encoded by p55gag.
Together, these data demonstrate that despite lower
in vitro accumulation in HEK293 cells, the HTI immu-
nogen was able to induce robust and broadly distributed
T-cell responses in DNA.HTI vaccinated mice, compar-
able in their magnitude to a mixture of plasmids ex-
pressing full-length proteins. In addition, the data show
that the present HTI subunit design was able to prevent
the strong Gag dominance that was induced by the full-
length immunogen approach. The data also show that
despite lower relative activity, HTI induces a humoral
response that may serve as a tool to monitor vaccination
outcome in future vaccine trials.
MVA.HTI boost increases responses after DNA prime
Poxvirus-vectors have shown great potential as HIV-1
vaccines and are an attractive choice to induce strong
CD8+ T-cell responses [42,60,61]. MVA.HTI (M) was gen-
erated and used in C57BL/6 mice to compare different
heterologous prime-boost combinations with DNA.HTI
(D). Vaccines were delivered using 100 μg of DNA.HTI
and 106 pfu of MVA.HTI by IM injection (Figure 4A).
Responses were measured 2 weeks after the last vaccin-
ation using pools of overlapping peptides (147 peptides,
Figure 3 (See legend on next page.)
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Figure 3 Balanced immunogenicity upon vaccination with DNA.HTI in mice. (A) Vaccination schedule. Groups of mice (n = 5) were
vaccinated twice by IM injection followed by in vivo electroporation (EP) using 20 μg DNA.HTI and a mixture of 3 plasmids encoding for
full-length p55gag, Pol and a Nef-Tat-Vif fusion protein (DNA.COMB). Cellular immune responses were measured from thawed splenocytes
by IFN-γ ELISPOT 2 weeks after the 2nd vaccination using 8 peptide pools covering the HTI sequence. (B) The number of HTI positive responses
(reactive pools) in mice immunized with 20 μg DNA.HTI or DNA-COMB is shown. (C) Total magnitude of the HTI-specific IFN-γ responses is depicted
from the mice shown in panel B. (D) Comparison of the IFN-γ responses in mice vaccinated with DNA.COMB targeting the regions included in the HTI
(grey bars) and the total IFN-γ specific response to peptide pools spanning the complete Gag, Pol, NTV. (E) Distribution of HTI-specific induced IFN-γ
responses against Gag, Pol, Vif and Nef in mice from panel B is shown (DNA.HTI in mice 1–5; DNA.COMB in mice 6–10) using peptide pools spanning
the protein sequences included in HTI. (F) Binding antibodies to Gag were detected by Western immunoblot. The membranes contain Gag proteins
from HEK293 cells transfected with 1 μg of p55gag plasmid producing the unprocessed p55gag protein or transfected with a Gag-Prt plasmid expressing
p55gag, the processing intermediate p37gag (p24gag and p17gag) and processed p24gag proteins. Membranes were probed with human sera from an
HIV-infected individual or pooled plasma from mice immunized with 20 μg of DNA.HTI and DNA.COMB (at a 1:100 dilution). (G) Anti-HIV-1 p24gag
antibodies were measured in pooled plasma from DNA.HTI and DNA.COMB vaccinated C57BL/6 mice by a standard clade B p24gag ELISA.
The graph shows absorbance (optical density, OD).
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including the junctional regions).
DD immunization elicited responses in 3 out of 5
mice, whereas 100% of the animals showed responses
after DDD vaccinations with a trend to increased levels
compared to a DD regimen only (Figure 4B-C). A subse-
quent MVA.HTI boost after two or three DNA prime
vaccinations led to higher responses with significantly
higher magnitudes (median total magnitude of 777 vs
2,865 IFN-γ SFC/million splenocytes after DDD and
DDDM, respectively, p = 0.0087; Figure 4C). To rule out
that the boosted response observed was driven by the
absolute number of immunizations rather than an heter-
ologous prime-boost strategy, the immunogenicity ofTable 5 Distribution of HTI-specific responses and number of
HTI segments HIV-1 protein HTI pool (#peptides/poo
S1a Gag-p17 Pool1 (10)
S2 Gag-p24 Pool2 (12)
S3 Gag-p24
S4 Gag-p24
S5 Gag-p24
S6 Gag-p24
S7 Gag-p15 Pool3 (3)
S8a Prt Pool4 (6)
S9a RT Pool5 (11)
S10a RT
S11 RT
S12 Int Pool6 (4)
S13 Int
S14 Vif Pool7 (4)
S15 Vif
S16a Nef Pool8 (2)
asegments with increase in HTI-specific responses in DNA.HTI and DNA.COMB.DDD, DDDD vs. DDDM vaccine regimens was assayed
in an independent experiment. While a fourth DNA vac-
cination did not augment responses any further, a sig-
nificant increase in the total magnitude of responses was
found after a single MVA.HTI boost (Figure 4D), reach-
ing in some animals more than 4,000 SFC/106 spleen
cells. As observed for the DDD only vaccinations, a
similar balanced and broad response to most of the
protein-subunits included in the immunogen was ob-
served in all animals boosted with MVA.HTI (Figure 4E).
Nef and Gag-p15 specific responses were only detected
in 1 of 6 animals, possibly due to the short length of
these two regions (13 and 27 amino acids, respectively;
Table 3).mice with responses to each protein subunit
Number of animals with positive response (n = 5)
l) DNA.COMB DNA.HTI
0 2
5 5
0 0
2 5
2 4
0 0
2 2
0 1
Figure 4 (See legend on next page.)
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Figure 4 HTI responses are boosted by MVA.HTI vaccination. (A) Vaccination schedule of mice (n = 6/group) vaccinated with different
prime/boost regimens including: 2xDNA (DD), 3xDNA (DDD), 4xDNA (DDDD); DNA prime followed by MVA boost (DDM and DDDM). 147 peptides
(15-mers, overlapping by 11 residues) spanning the entire HTI sequence (including the leader sequence and linkers regions) were used in an IFN-γ
ELISPOT assay to assess immunogenicity of the different regimens. Data from 1 animal in the DD group was not evaluated due to high
background result in the ELISPOT assay. Breadth (B) and magnitude (C-E) of induced HTI-specific IFN-γ responses in different groups of
mice to a set of 16 peptide pools spanning the different protein segments is shown either as total HTI-specific responses (C, D) or as
response to individual proteins (E). Bars represent median values. Median with interquartile range is shown in panel E. Panel D is an independent
mouse experiment conducted to compare responses after DDD, DDDD and DDDM vaccination.
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T cells in rhesus macaques
Next, four outbred Indian rhesus macaques with differ-
ent MHC class I haplotypes (Table 6), none expressing
Mamu-B*08 [62], were vaccinated via the IM route com-
bined with in vivo electroporation at 0, 1 and 3 months
with DNA.HTI (Figure 5A). A macaque IL-12 encoding
DNA plasmid was co-administered as molecular adjuvant.
The HTI-specific cellular immune responses were mea-
sured in PBMC upon stimulation with the immunogen-
matched peptide pools and analyzed by intracellular
cytokine staining. Analysis of the immune responses at
2 weeks after the 2nd DNA vaccination showed robust in-
duction of HTI-specific IFN-γ+ T cells in all macaques
(Figure 5B). The responses increased with the 3rd DNA
vaccination yielding a range of 0.4-1.5% of total T cells re-
active to HTI peptides.
In three (R678, R679, R680) out of the four animals,
the responses induced by HTI vaccination were mediated
primarily by CD8+ effector memory T cells (EM, CD28−
CD95+) with significant contributions by the CD4+ and
CD8+ central memory T cell subsets (CM, CD28+CD95+)
(Figure 5C). In contrast, macaque R681 developed re-
sponses dominated by CD4+ T cells and, overall, had the
lowest level of recognition of the HTI epitopes. Although
we noted a contraction of the responses over the following
4.5 months, these responses persisted and were still in the
range as measured after the DD vaccination (range 0.1-
0.6% IFN-γ T cells), supporting the longevity of the DNA-
vaccine induced immunity using an IM/EP approach
[45,63]. At this time point, the animals were boosted with
recombinant MVA.HTI (Figure 5A), which led to a 3- to
20-fold increase in the response, reaching 0.4-3.2% IFN-γ
T cells (Figure 5C). In two of animals (R678, R680) the
levels were higher than the peak response after three DNA
immunizations. The responses persisted over the 3 monthsTable 6 Age, gender and haplotypes of macaques
Animal Age (yrs) Sex A*01 A*02 A*08
R678 3 Male Neg Neg Pos
R679 3 Male Neg Neg Neg
R680 3 Male Neg Neg Neg
R681 3 Male Neg Neg Posof follow-up and were successfully expanded in all 4
animals by a 2nd MVA.HTI vaccination. Macaque R680
showed an exceptionally high persistence of responses
(~2% of IFN-γ+ T cells), which were only weakly boosted
by the 2nd MVA boost. Overall, MVA.HTI was powerful
in expanding DDD induced responses with limited benefit
noted upon the 2nd MVA.HTI boost.
HTI vaccine induces antigen-specific memory T cells with
cytotoxic potential
We also analyzed the cytotoxic potential of the vaccine-
induced T cell responses using Boolean gating strategies.
Subsets of the antigen-specific CD8+ (Figure 6A) and CD4+
(Figure 6B) T cells were characterized by their granzyme B
(GzmB) content and ability to degranulate, as determined
by surface expression of CD107a after antigen stimulation
[64]. This analysis revealed the majority of IFN-γ+ CD8+ T
cells being double positive for CD107a+ and GzmB+
(Figure 6A), both after DNA prime and MVA boost
vaccinations. Similar to the memory subsets, these cyto-
toxic phenotypes did not significantly change over time.
The analysis of antigen-specific CD4+ T cells (Figure 6B)
showed that although the majority of these cells were
GzmB− and CD107a− , this subset also contained a small
fraction of single CD107a+ or double positive (GzmB+
CD107+) cells. In this aspect the four animals showed a
consistent pattern of effector functions, even though
CD4+ T cells dominated the vaccine-induced response
in animal R681.
HTI vaccine induces broadly distributed responses in
rhesus macaques
Finally, the distribution of responses across the different
protein-subunits contained in the HTI immunogen was
assessed at the peak after the DNA vaccinations (DDD)
and after the MVA.HTI boosts (Figure 7). A set of 16A*11 B*01 B*03 B*04 B*08 B*17
Neg Neg Neg Pos Neg Pos
Neg Neg Neg Neg Neg Neg
Neg Neg Neg Neg Neg Neg
Neg Neg Neg Neg Neg Neg
Figure 5 (See legend on next page.)
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Figure 5 HTI vaccine induces robust memory T cell responses in rhesus macaques. (A) Vaccination schedule. Four macaques (R678, R679,
R680, R681) were vaccinated 3x (0, 1, 3 months) with DNA.HTI and IL-12 DNA and subsequently with two MVA.HTI boosts. Cellular immune responses
were measured by intracellular cytokine staining after the different vaccinations as indicated. (B) The frequency of HTI-specific IFN-γ+ T cells
was measured after the DNA vaccinations using peptide pools covering the complete HTI sequence. The HTI-specific CD4+ (open bars)
and CD8+ (filled bars) T cells are shown for each animal as number of reactive peptide pools. (C) The frequencies of HTI-specific IFN-γ+ T cells with
central memory (CM; CD28+CD95+) and effector memory (EM; CD28−CD95+) phenotype are shown over the course of the study.
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segment of the HTI sequence (Table 3), was used to
measure responses by flow cytometric intracellular cyto-
kine staining assays. The results show that three DNA
vaccinations induced T cell responses targeting all the
proteins represented within HTI, except Nef and recog-
nized a range of 4–7 of the 16 segments (Figure 7,
Table 7). Of note, Nef is represented by a single segment
of only 13 aa (and includes only three known CTL
epitopes [55] restricted by the same B*07 supertype in
humans), whereas other proteins were covered by several
segments of various lengths (Table 7). Upon the 1st MVA.
HTI boost, the magnitude of the pre-existing responses
was increased in all the animals (range 6–8 segments) and
additional responses were found in two animals (R678,
R680), albeit at low levels. After the 2nd MVA.HTI boost,
macaques R681 showed 3 additional responses, while
some of the new responses found after the 1st MVA.HTI
boost in R678 and R680 were not detectable. Overall,
DNA prime-MVA boost showed that 13 of the 16 seg-
ments of HTI were immunogenic in macaques (Table 7).
As expected the majority of the HTI-specific responses
was mediated by CD8+ IFN-γ+ T cells in R678, R679 and
R680 and by CD4+ IFN-γ+ T cells in R681.
Because the HTI design is based on human, HLA-
restricted T cell reactivity data, we did not further fine-
map the HTI-segments to identify all CTL responses at
the single epitope level in the context of each macaque
MHC class I allele. Thus, the full breadth of the broad
responses induced by HTI in macaques (81% of HTI
segments) may be underestimated.
HTI vaccine induces humoral responses in rhesus
macaques
We also tested the plasma from the vaccinated macaques
upon DNA prime and upon MVA boost for the develop-
ment of humoral responses to HTI protein (Figure 8A).
We found that upon 3 DNA vaccinations, 3 of the 4 ani-
mals (R678, R679, R801) developed low levels of anti-
bodies specific for HTI protein. Upon MVA boost all 4
animals showed greatly increased responses. The plasma
was further tested by ELISA for its ability to recognize
p24gag. One of the macaques R678 also showed positive
ELISA responses after the MVA boosts, indicating that
the HTI vaccine sequence also induced humoral immune
responses at least against some of its components.Together, we present here the development and pre-
clinical testing of a novel HIV-1 T-cell immunogen that
has been rationally designed to maximize the induction
of effective anti-viral T cell immunity. Its design is based
on some of the largest available datasets of human cellu-
lar immunity to HIV-1, which allowed for the identifica-
tion and inclusion of the most vulnerable T cell targets
within the viral proteome that are associated with con-
trol of viremia. Thus, the HIVACAT T-cell Immunogen
(HTI) differs conceptually from previous immunogen
design approaches that have used full proteins sequences
[23-25] or very short protein segments only [29,65,66].
This extends to the most promising approaches, includ-
ing the one developed by Hanke et al. that focuses on
conserved regions of the viral proteome [42]. In that de-
sign, some regions are included that do not seem to in-
duce broad and strong immune reactivity in natural
HIV-1 infection [36] and do not emerge as particularly
beneficial targets [28]. Although the reasons for this re-
duced immunogenicity are unknown and could include
subdominant beneficial targets [3], the relevance of such
portions of vaccine inserts needs to be revisited. Similarly,
immunogens that focus on highly conserved elements
(CE) within Gag-p24 were chosen in part because of their
preferential reactivity by controllers and since immune
response to conserved regions have been associated with
virologic control [17-20,28]. However, screening data
showed that only select CE to be more frequently targeted
by HIV controllers [27], in line with recent data suggesting
that sequence conservation alone is not a reliable measure
of vulnerability [67,68]. Finally, the favorable design of
HTI is further supported by emerging data from studies
in post-vaccination samples in the STEP and Phambili
trials [69]. In those analyses, the subjects’ in vitro antiviral
activity (measured by viral replication inhibition assay and
associated with in vivo viral control [70] was directly cor-
related with the extent to which the CD8 T cell response
was focused onto the HTI sequence, but not with the
magnitude of responses to the rest of the viral proteome.
The incorporation of T cell reactivity data from natural
HIV-1 infection may make the HTI sequence especially
interesting for therapeutic and eradication approaches
[71]. In this context, the inclusion of relatively conserved
regions may help to cope with the consequences of viral
evolution of both circulating and reactivated viruses [72]
in chronically infected individuals. At the same time, the
Figure 6 HTI vaccine induces T cell responses with cytotoxic potential. HTI-specific IFN-γ+ CD8+ (A) and CD4+ (B) subsets of T cells harboring
granzyme B (GzmB) and/or expressing CD107a are shown for each animal.
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Figure 7 Breadth of HTI-specific T cell responses in vaccinated macaques. Mapping of HTI-specific T cell responses after the 3rd DNA prime
and 1st and 2nd MVA boost using peptide pools covering each segment (S1-S16). The percentage of IFN-γ+ CD4+ (open bars) and CD8+ (filled bars)
T cells specific for each segment is shown. For a summary of data see Table 7. Asterisk denotes new responses emerging after MVA boost vaccination.
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may also help the induction of neutralizing humoral
immunity in preventive settings [6,53]. In that setting,
the focus on most vulnerable regions of the viral prote-
ome could prove crucial if sterilizing immunity cannot be
obtained as the induced T-cell responses may help to
reduce viral fitness and lower viral set point in break-
through infections. The induction of such effective anti-
viral immunity, even though not sterilizing, would stillhave a far-reaching impact on the epidemic, both by redu-
cing rate of disease progression as well as by lowering the
likelihood of further virus transmission. Of note, and al-
though the development of HTI was largely based on im-
mune data from a HIV-1 clade B-infected cohort in Peru,
our results are supported by additional analyses in an
European clade B-infected cohort (shown here) and a US-
based cohort previously described [36]. In addition, viral
fitness data, which have been published since the initial
Table 7 Breadth of cellular immune responses after DNA.HTI prime and MVA.HTI boost using HTI segment-specific
peptide pools
Animal Vaccine Gag Pol Vif Nef # of positive
segmentsp17 p24 p15 Prt RT Int
1a 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
78b 14 11 60 14 15 27 55 17 55 34 34 17 23 19 13
R678 DNA + + + + + + 6
MVA + + +c + + + +c + 8
R679 DNA + + + + + + + 7
MVA + + + + + + + 7
R680 DNA + + + + 4
MVA + +c + +d,e + + +d,e 7
R681 DNA + + + + + + + 7
MVA + + + +d + + + +d +d 9
asegment number, S1-S16.
bnumber of amino acids per segment.
cnew response detectable after 1st MVA boost only.
dnew response detectable after 2nd MVA boost.
enew response detectable after 1st and 2nd MVA boost.
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and its preferential focus on sites that are highly sus-
ceptible to debilitating sequence mutations [56,68]. Fur-
thermore, it is also reassuring that HTI in at least some
regions overlaps with the HIVCons [42] the Conserved
Elements [17,18] and other conserved regions previ-
ously proposed to induce protective T cell responses [31]
despite the differences strategies that were the base for
these designs.
An important aspect of the present vaccine candidate
is its focus on fewer but possibly more effective targets
than those that are generally induced by full-protein im-
munogens. Of particular importance may be the avoid-
ance of responses to highly immunogenic and at the same
time variable targets, as these may effectively misdirect
the immune response [19]. This is especially the case for
HIV-1 Nef, which contains multiple hot spots of high
T-cell reactivity. In fact, past reports show that peptide
sets spanning Nef contain the single most dominant 18-
mer peptides that can elicit responses in more than 50% of
the tested individuals [36]. This number is likely even an
underestimation as responses to more variable regions
are missed by the use of monomorphic peptide test sets
[73,74]. The same may apply to responses targeting enve-
lope which has shown surprisingly strong immunogenicity
in some vaccination trials but which, in our analyses, did
not yield any beneficial T cell targets [24,28,75]. The re-
activity to potential decoy targets in envelope needs special
consideration when using full-length envelope sequences
for the induction of humoral responses. In this regard,
shorter envelope immunogen designs (i.e. MPER [76]) may
provide and advantage as there is less chance of diverting
the T cell immune response to less effective epitopes.The concern of decoy responses calls into question
strategies that intend to overcome diversity by including
multiple variants of the same sequence [32-35] as this
may further prevent the induction of more beneficial
T-cell specificities. As such, it may be beneficial to deal
with HIV-1 sequence diversity by ignoring it, rather than
trying to incorporating it into vaccine immunogens [77].
The expansion of responses to decoy targets has also
important implications when considering HTI as a thera-
peutic vaccine. As suggested by previous therapeutic trials
it may prove difficult to remodel the T cell response pat-
terns induced during chronic HIV-1 infection by thera-
peutic vaccination [78-81]. In this case, the use of a vaccine
vector with relatively low immunogenicity may help to spe-
cifically boost HTI-specific responses while avoiding the
expansion of less beneficial T cell specificities that may
occur when using viral vectors with more systemic im-
mune activation. For this reason, we elected to express
HTI first in a DNA plasmid vector as these allow for
repeated administrations without generating vector immun-
ity. In addition, DNA vaccines expressing different forms
of simian immunodeficiency virus antigens decrease
viremia upon SIVmac251 challenge [45,59].
Overall, murine data accurately predicted the outcome
of vaccination in macaques, as in both species broadly
directed responses of high magnitude were detected. Espe-
cially encouraging was the avoidance of overly immuno-
dominant responses to single epitopes, reflected by the
fact that in the macaque model 81% of the HTI-segments
were recognized in the context of heterogeneous MHC
haplotypes and after testing only four different animals.
Why one animal failed to induce strong CD8 T cell re-
sponses and instead mounted broader CD4 T cell activities
Figure 8 Humoral responses in HTI vaccinated macaques. (A)
Binding antibodies to HTI were detected by Western immunoblot.
The membranes contain enriched HTI-FLAG proteins from HEK293
cells. The membranes were probed with plasma (at a 1:100 dilution)
from individual macaques collected at 2 weeks after 3rd DNA.HTI
(DDD) and 1st MVA.HTI (M) boost. (B) Anti-HIV-1 p24gag antibodies
were measured in different plasma samples, including pre-immune,
after DNA.HTI and after MVA.HTI vaccinations of macaque R678 by a
standard p24gag ELISA. The graph shows absorbance (optical
density, OD).
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mains unclear. Further analyses in host genetics and/or
immune homeostasis (cytokine levles, etc.) could possibly
help explain this atypical response pattern and provide
some leads to understand the only partial response rates
even in the most potent vaccination strategies in SIV in-
fected animals [82,83] Regardless of this, the avoidance of
strong immunodominance effects will be a prerequisite
for broad T cell responses in vivo a requirement that HTI,
at least in mice and macaques, seems to fulfill as allcomponents of the vaccine were evenly targeted. These
observations need to be verified in human clinical trials as
the antigen processing preferences and T cell receptor
(TCR) repertoires in humans may be different. The same
is true for the HTI-elicited high magnitude of antigen-
specific effector memory CD8+ T cells with cytotoxic
potential as well as CD4+ CM T cells. Hansen et al.,
using RhCMV vectored vaccines, reported that such effector-
memory T cell responses located at the portal-of-entry are
able to mediate viral control after SIV amplification in
intra-rectally challenged rhesus macaques [83,84]. Of note,
RhCMV vectored vaccines induced extremely broad re-
sponses with a significant altered immunodominance hier-
archy compared to response to natural HIV infection,
further suggesting that the fine specificity of the vaccine-
induced HTI/HIV specific T cell response may prove
crucial. Yet, since the HTI design is human data-driven,
challenge studies in the macaque model are not really
feasible as a) there are no comparable immune reactivity
data from sufficiently large and out-bred monkey cohorts
available and b) the evolution of SIV variants used in mon-
key models does not reflect the adaptation processes of
HIV to the human population [85]. Thus, human clinical
trials are being initiated in the therapeutic vaccination set-
ting as a proof-of-concept to test whether this novel con-
cept of HIV T cell immunogen design will indeed lead to
the induction and refocus of broadly co-dominant T cell
responses that can effectively suppress viral replication.
Conclusions
We present here the design and preclinical-testing of a
novel approach to HIV vaccine design, which is based
on the identification of beneficial T cell responses and
vulnerable viral targets and their subsequent inclusion in
a refined subunit immunogen sequence. Our data show
that the immunogen is capable to induce broadly and
evenly distributed responses without being affected from
strong immunodominance effects. Prime-boost strategies
using DNA and MVA vectors elicit responses that ex-
ceed magnitudes by most other vaccine concepts and
which are of a differentiation phenotype associated with
vaccine-induced control of SIV infection in the macaque
model. These data support the further development of
this and other related functional-data based T cell vac-
cine approaches.
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